To animate the Banner

Picture Name

Apply for post


Recruitment Position

Place of work

Number of Recruits

Salary Treatment

ICP-248

ICP-248 is a new oral and highly selective BCL2 inhibitor. BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the occurrence and development of a variety of malignant hematological tumors. ICP-248 selectively inhibit BCL2 and restore the mechanism of tumor cell death, so as to exert anti-tumor effect. The clinical trial of ICP-248 combined with orbitinib in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has completed the first patient administration in China. ICP-248 demonstrated good safety and efficacy in a phase I study. All patients achieved an objective response at the 100 mg once daily dose, with a complete response rate (CR) of 50%. The ICP-248 aims to treat a variety of malignant blood tumors with single drug or combination, and has a broad development space and significant potential in combination with Obutib.

Gender
Marriage
kg
cm
Please upload a resume file smaller than 5M ~